特例承認 against Huaiza K.K.
ファイザー株式会社 (医薬品医療機器等法)
医薬品医療機器等法Ministry of Health, Labour and WelfareFebruary 10, 2022
Action summary
- Company
- Huaiza K.K.RomanizedOriginal: ファイザー株式会社Corporate Number: 5011001126167
- Governing law
- 医薬品医療機器等法医薬品医療機器等法
- Action type
- 特例承認特例承認
- Action date
- February 10, 2022
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
Machine-translated summary — verify against original
Name of the treatment drug for COVID-19: Paxlovid Pack, Generic name: Nirmatrelvir, Ritonavir, Applicant: Pfizer Inc., Application date: January 14, 2022 (Reiwa 4).
Show original Japanese text
新型コロナウイルス感染症に係る治療薬の販売名：パキロビッドパック、一般名：ニルマトレルビル、リトナビル、申請者：ファイザー株式会社、申請日：令和４年１月14日
Source
Original Ministry of Health, Labour and Welfare announcement (in Japanese)The original Japanese disclosure is the authoritative record.
Watch this company
Get an email when Huaiza K.K. has new enforcement actions or registry changes (representative, address, business status). Sign-in is via a one-time email link — no password.
Language
日本語版を見る (Japanese)Company info
- English name
- Huaiza K.K. Romanized
- Japanese name
- ファイザー株式会社
- Corporate Number
- 5011001126167
- Registered address
- 東京都渋谷区代々木３丁目２２番７号
About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.